›› 2011, Vol. 31 ›› Issue (11): 1532-.doi: 10.3969/j.issn.1674-8115.2011.11.006

• Monographic report (Bipolar disorder) • Previous Articles     Next Articles

Changes of plasma brain-derived neurotrophic factor in patients with bipolar disorder type Ⅰ

WANG Zuo-wei1,2, LI Ze-zhi1, LIN Zhi-guang1, WU Zhi-guo1, YUAN Cheng-mei1, HONG Wu1, LI Chun-bo1, FANG Yi-ru1   

  1. 1.Shanghai Mental Health Centre, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China；2.Hongkou District Mental Health Center, Shanghai 200083, China
  • Online:2011-11-28 Published:2011-11-29
  • Supported by:

    National Natural Science Foundation of China, 30971047；National High Technology Research and Development Program of China, “863” Program, 2006AA02Z430；Shanghai Jiaotong University School of Medicine Foundation, 2008-6, YBPY2010010；Shanghai Hongkou District Medical Foundation, 2010-91

PDF (PC)

1085

Abstract:

Objective To explore the relationship between plasma brain-derived neurotrophic factor (BDNF) and manic episode of bipolar disorder type Ⅰ. Methods With comprehensive clinical review and structured clinical interview for DSM-Ⅳ axis Ⅰ disorders patient version (SCID-Ⅰ/P), 28 patients with manic episode of bipolar disorder type Ⅰ were enrolled (case group), and were treated with lithium and quetiapine. Another 30 gender- and age-matched healthy volunteers were served as controls. Plasma mass concentrations of BDNF in case group and control group were detected by ABC-ELISA before treatment and 2 weeks, 4 weeks and 8 weeks after treatment, and the relationship between plasma mass concentration of BDNF and Young mania rating scale (YMRS) was analysed in case group. Results The plasma mass concentrations of BDNF in case group were significantly higher than those in control group before treatment and 8 weeks after treatment (P<0.05), while there was no significant difference in the plasma mass concentrations of BDNF between two groups 2 weeks and 4 weeks after treatment (P>0.05). In case group, the plasma mass concentrations of BDNF before treatment and 2 weeks and 8 weeks after treatment were not related to the score of YMRS (P>0.05), while the plasma mass concentration of BDNF 4 weeks after treatment was significantly related to the score of YMRS (r=－0.450, P<0.05). Conclusion The episode state of mania in patients with bipolar disorder type Ⅰ is not linearly associated with the plasma level of BDNF, and further studies with large samples are necessary to elucidate the relationship between them.

Key words: bipolar disorder, manic episode, brain-derived neurotrophic factor, plasma